TNF and inflammatory bowel disease: Overall, the rate of AEs leading to discontinuation of biologics in patients with PSC-IBD was higher (17.6%, 95% CI: 13.0–23.5) than that reported in the literature for non-PSC-UC cohorts (for infliximab 4% (95% CI: 1–14) and for vedolizumab 5% (95% CI: 3–7).25 Vedolizumab was associated with a lower drug discontinuation rate compared to the anti-TNF alpha inhibitors (9.8%, 95% CI: 2.5–31.8 vs. 18.3%, 95% CI: 13.4–24.5, p=0.03).